Resources
At SJJ Solutions we believe that data is key. For that reason, we extensively test all our products according to the highest possible standards available before they enter the market. This has resulted in multiple publications in which we put our products to the test for stability and particle data.
Press releases
Zero Residual™ silicone oil-free syringe, tailored for intravitreal injections, receives CE under the new requirements of EU MDR
THE HAGUE, The Netherlands, December 1, 2022 – SJJ Solutions B.V. presents the world’s first CE-approved, silicone oil-free, syringe that is specifically tailored for intravitreal
Publications
Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties
Abstract Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must
Accuracy and residual volume of intravitreal injection syringes in administration of very small volumes
Introduction Intravitreal injections (IVIs) are widely used to deliver therapeutic agents for various retinal conditions. The syringe accuracy is a critical factor in achieving optimal
Accuracy, Precision, and Residual Volume of Commonly Used Syringes for Intravitreal Injections and the Impact on Intraocular Pressure
Purpose To compare accuracy, precision, and residual volume of commonly used syringes for intravitreal injections (IVIs) and to assess the intraocular pressure (IOP) rise by variations in volumes delivered. Design Experimental
A Silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics
Intravitreal injections (IVI) of biologics targeting vascular endothelial growth factor (anti-VEGF) led to a paradigm shift in the management and prognosis of prevalent retinal conditions.
Release of silicone oil and the off-label use of syringes in ophthalmology
Abstract Background/aims: To assess silicone oil (SO) release by different brands of syringes used for intravitreal injection under different handling conditions. Methods: Eight syringes were analysed: from
News & Media
SJJ Solutions ontvangt subsidie via het Kansen voor West III programma
Leeftijdsgebonden maculadegeneratie (AMD) is een complexe oogaandoening die de macula beschadigt, wat leidt tot verminderd zicht. Leeftijd is de belangrijkste risicofactor. Natte AMD kan worden behandeld met VEGF-remmers, dit is echter een kostbare behandeling en een belasting voor de gezondheidszorg.
OUS-researchers have developed an injection syringe in collaboration with a Dutch company
SJJ Solutions skal selge en norskutviklet øyesprøyte som blant annet professor Jan Terje Andersen står bak. Zero Residual-sprøyta er skreddersydd for å injisere små volum av antistoffbaserte legemidler i øyet. Sprøyta kan brukes for å behandle aldersrelatert makuladegenerasjon i tillegg
Eerst 5, toen 6 en nu nog één extra: RIVM en Inspectie keuren toch 7 doses goed uit flesje Pfizer-vaccin
Het is toch toegestaan om zeven doses uit een flacon Pfizer-vaccin op te trekken. Dat melden het RIVM en de Inspectie Gezondheidszorg en Jeugd (IGJ) aan EenVandaag. Eerder werden er vijf uitgehaald en later mochten dat er zes worden. Vorige
This syringe manufacturer accomplishes to get 7 doses of pfizer vaccine from a single vial
Het Europees Medicijnagentschap heeft deze week goedgekeurd dat er zes in plaats van vijf doses uit een flacon van het Pfizer-vaccin gehaald kunnen worden. Maar volgens Jasper Schootstra van SJJ Solutions kunnen dat er zelfs zeven worden. Met een speciale
SJJ Solutions signs industry development agreement with Inven2
The Dutch medical device company SJJ Solutions, the Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity and Homeostasis of both Oslo University Hospital and University of Oslo, have entered an industry development agreement. The industry
Choosing a syringe for intravitreal injection
The ideal syringe for administering intravitreal injections does not exist. With improved awareness of the drawbacks of existing devices and the characteristics desired for intravitreal use, however, syringe manufacturers are stepping up to design products that will help maximize the